We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

36 hedge funds and large institutions have $4.68M invested in AIM ImmunoTech in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 35 → 36 (+1)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

34% less capital invested

Capital invested by funds: $7.12M → $4.68M (-$2.44M)

Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RJFSA
Raymond James Financial Services Advisors
Florida
+$36K
2
TSS
Two Sigma Securities
New York
+$29.9K
3
FWM
ForthRight Wealth Management
Georgia
+$19.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$18.3K
5
Jane Street
Jane Street
New York
+$9.98K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$377K
2
Renaissance Technologies
Renaissance Technologies
New York
-$296K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$89K
4
Bank of America
Bank of America
North Carolina
-$14.4K
5
Millennium Management
Millennium Management
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.55M – – –
Morgan Stanley
2
Morgan Stanley
New York
$1.25M -$377K -3,932 -20%
BlackRock
3
BlackRock
New York
$638K -$11.4K -119 -1%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$297K +$8.73K +91 +2%
State Street
5
State Street
Massachusetts
$135K – – –
Verition Fund Management
6
Verition Fund Management
Connecticut
$119K – – –
BCM
7
Bridgeway Capital Management
Texas
$118K -$9.6K -100 -6%
Renaissance Technologies
8
Renaissance Technologies
New York
$94K -$296K -3,080 -72%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$91K – – –
Northern Trust
10
Northern Trust
Illinois
$69K – – –
VF
11
Virtu Financial
New York
$43K +$3.84K +40 +8%
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$36K – – –
Rockefeller Capital Management
13
Rockefeller Capital Management
New York
$31K – – –
SWM
14
SeaCrest Wealth Management
New York
$31K – – –
RJFSA
15
Raymond James Financial Services Advisors
Florida
$29K +$36K +375 New
TSS
16
Two Sigma Securities
New York
$24K +$29.9K +312 New
Bank of New York Mellon
17
Bank of New York Mellon
New York
$20K -$2.21K -23 -8%
CAPTRUST Financial Advisors
18
CAPTRUST Financial Advisors
North Carolina
$16K – – –
FWM
19
ForthRight Wealth Management
Georgia
$16K +$19.2K +200 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$15K +$18.3K +191 New
LPL Financial
21
LPL Financial
California
$12K -$480 -5 -3%
CB
22
Community Bank
New York
$10K – – –
TCM
23
Traynor Capital Management
Pennsylvania
$9K – – –
SFG
24
SNS Financial Group
Minnesota
$8K – – –
Wells Fargo
25
Wells Fargo
California
$8K +$384 +4 +4%
1
2

AIM Hedge Fund Activity: Q2 2022 in Review

36 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2022, worth a combined $4.68M — down 34% from $7.12M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AIM positions and 5 closed out — a net gain of 1 holder — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $36K. The largest seller was Morgan Stanley, cutting an estimated $377K.

  • 36 institutional investors held AIM ImmunoTech (AIM) as of Q2 2022, up from 35 in Q1 2022.
  • Funds reported $4.68M of AIM ImmunoTech stock for Q2 2022, down 34% quarter-over-quarter.
  • 6 funds opened new AIM ImmunoTech positions in Q2 2022 and 5 closed out, a net change of +1 holder.
  • The largest AIM ImmunoTech buyer in Q2 2022 was Raymond James Financial Services Advisors, an estimated $36K added.
  • The largest AIM ImmunoTech seller in Q2 2022 was Morgan Stanley, an estimated $377K sold.

Based on aggregated 13F filings for Q2 2022.